Micell Technologies has initiated patient enrolment for a clinical trial of MiStent DES, its investigational drug-eluting stent for the treatment of coronary artery disease.

The prospective, open-label, non-randomised and single-arm study will enrol 30 patients with documented stable or unstable angina pectoris or ischemia.

The primary endpoint of the study will be in-stent late lumen loss, while the secondary endpoints will be major adverse cardiac events and revascularisation rates.

The MiStent DES is a combination of bio-absorbable polymer and an approved drug, sirolimus. It is designed to deliver a precise therapeutic solution for coronary artery disease treatment.